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ABSTRACT  
Stem cell based therapies for Parkinson’s disease are moving into a new and exciting era, with 
several groups pursuing clinical trials with pluripotent stem cell (PSC)-derived dopamine neurons. As 
many groups have ongoing or completed GMP-level cell manufacturing, we highlight key  clinical 
translation considerations from our recent fourth GForce-PD meeting. 
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Parkinson’s Disease (PD) is particularly attractive for stem cell based therapies, since  its core 
pathology involves  the loss of highly specialized dopamine (DA) neurons in the substantia nigra.  DA 
neuronal loss is responsible for many of the pathophysiological features of the disease, such as  the 
rigidity and  bradykinesia, which can be treated with great effect in early disease using dopaminergic 
drugs. However, these drugs do not replace dopamine only at the site of greatest loss nor do they 
mimick the normal release of dopamine at these sites. As a result their use results in side effects 
such as dyskinesias and behavioural problems. In contrast, targeted dopamine neuronal 
replacement therapies have the potential to address these shortcomings of the dopaminergic drugs. 
Proof of principle studies supporting this therapeutic strategy have used early fetal brain tissue. In 
particular, fetal ventral mesencephalic allografts (hfVM) can release dopamine and have shown long 
term efficacy and survival, as well as improvements in quality of life and some non-motor features of 
PD (reviewed in (Barker et al., 2015)). However, such transplants have not always worked and have 
even generated side effects (e.g. graft induced dyskinesias) with signs of disease related pathology in 
the transplanted cells years after being implanted (Barker et al., 2015). A number of tractable issues 
may explain this variability in clinical response, and efforts to resolve these issues led to 
TRANSEURO, a new trial in Europe that has now grafted 11 patients with hfVM over the last 2 and a 
half years. 
However, the use of fetal tissue is problematic, both in terms of the ethics and practical issues linked 
to its acquisition and broader use, as well as the inability to standardise it for clinical application. For 
example, in TRANSEURO, only 20 out of a planned 90 or more surgeries have taken place because of 
tissue supply. Thus, there is a need for an alternative tissue source, ideally one that can be readily 
manufactured to a defined specification at the scale needed to treat the large number of PD 
patients. 
One source that has gained prominence in recent years is the use of human pluripotent stem cells 
(hPSCs). hPSCs  are derived from early pre-implantation embryos (ESCs) or reprogrammed adult 
somatic cells (iPSCs), and they can be robustly differentiated into  authentic midbrain dopaminergic 
neurons using recently developed protocols (Kirkeby et al., 2012; Kriks et al., 2011). This work has 
been concentrated in a number of centres worldwide, and in 2014, major academic networks in 
Europe, US and Japan that share common therapeutic ambitions regarding hPSC-derived 
dopaminergic neurons for PD   decided to join forces. This new initiative, GForce-PD (www.gforce-
pd.com), recently had its fourth annual meeting in Kyoto. During this meeting, it became clear that 
many of the teams have advanced to the point where GMP manufacturing is now in 
progress/completed, and the discussions therefore centred around how to use these cells in first in 
human clinical trials while being compliant with each region’s national guidelines. The meeting 
revealed that all teams were planning trials with start dates in the next couple of years (see Table 1). 
However, some clinical trials using stem cells for PD outside of GFORCE-PD have already started, 
involving commercial groups (ISCO) or  academically led studies,, such as a new Chinese HLA 
matched hESC trial (NCT03119636).  
 
The roadmap to a clinical trial 
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The starting material for developing dopamine cells for the clinical trials planned within GForce-PD 
has been defined by whether it will be iPS or ES cell derived (Figure 1). Some groups are choosing to 
use and evaluate non-matched, HLA-matched, or autologous iPS cells, while others will use ES cells 
(Table 1). The use of autologous or HLA matched cells is thought desirable as it reduces the need for 
immunosuppression in the recipient, although debate remains on whether ongoing immune 
rejection of allogeneic intracerebrally transplanted developing neural tissue occurs, since   PD 
patients who had stopped taking immunosuppression for many years have had long term survival of 
fetal allografts (Li et al., 2016).  
 
Each team within GForce-PD has now developed GMP protocols for deriving authentic and 
functional midbrain dopamine cells from hPSC sources, along with cryopreservation and QC assays. 
These protocols involve differentiation to committed dopamine neuroblasts, which generates the 
best results in animal models of PD. The protocols are reproducible and scalable, although issues still 
exist around the most appropriate genetic testing of the starting material and/or final product. 
Questions under discussion, for example, include whether karyotyping and exclusion of 
tumourogenic mutations is sufficient, or if more in-depth analysis, such as next generation 
sequencing is required.  If the latter is needed, then what constitutes a significant genetic variant 
and what is non-consequential, and who should make this decision? Should standards be the same 
for ES and iPS cells as well as for cell banks where the final product can be tested extensively for 
safety in large numbers of animals, in contrast to autologous cell lines where this may not be 
feasible in every single cell line and patient? At the moment, there are no definitive answers, and 
groups have clearly pursued different strategies in the absence of any scientifically conclusive data 
or consensus from different national regulators, although international efforts may help resolve 
some of these issues in the next few years (Andrews et al., 2017). 
 
Although not the topic of this Forum, it is critical to mention that the protocols employed in all the 
studies within GForce-PD have worked well in a number of in vivo studies with no tumour formation 
or uncontrolled growth (Grealish et al., 2014; Kikuchi et al., 2017; Kirkeby et al., 2012; Kriks et al., 
2011; Steinbeck et al., 2015). It is also important to note the rigorous documentation of this level of 
safety along with consistent efficacy and reproducibility, since in its absence, anxieties about both 
issues arise, which occurred in two recent highly publicised stem cell trials in PD (Barker et al., 2016; 
Cyranoski, 2017). 
The protocols developed by the members of GForce-PD are now close to or completed at the level of 
GMP production, with the definitive preclinical efficacy and safety studies ongoing or planned to be 
completed over the next 6-36 months. Recruitment to an observational arm of PD patients is 
ongoing with the aim of selecting patients from this cohort for transplantation in the first in human 
studies.  
The work presented at this year’s GFORCE PD meeting also included for the first time the ongoing 
preclinical work by Summit for Stem cell. Most of these groups (Table 1), are looking to manufacture 
large batches of cryopreserved vials of dopamine precursors. The final clinical cell product will then 
be tested for stability, tumorigenesis, biodistribution, and toxicology in accordance with relevant 
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national regulatory agencies (e.g. FDA v MHRA v PMDA), with the results made publically available 
similar to what have done previously (Grealish et al., 2014; Kikuchi et al., 2017; Kriks et al., 2011; 
Steinbeck et al., 2015).  
This GMP level manufacturing of the cell product required for human trials is not a trivial exercise.  
DA cell production faces many of the same issues as other fields attempting to use cell based 
therapies. However, the efficiency of the protocols coupled to the relatively small number of cells 
needed to treat individual patients  means we can still use small scale manual manufacturing 
processes that employ standard culture flasks and incubators to make cells for hundreds of patients, 
which is more than sufficient for the planned trials. Nevertheless, if the therapy moves on to a phase 
III/market authorization phase, it will be necessary to further scale up the procedure and/or develop 
automated manufacturing systems.  
Goals of GForce-PD 
The 4 teams currently represented at this last GForce-PD meeting are all moving forward with the 
aim of undertaking their own clinical trials within the next 1-3 years. As progress is pursued, GForce-
PD serves 3 main purposes: 1) it critically appraises the pre-clinical evidence from all groups 
supporting the adoption of the derived cells as a dopamine replacement therapy, 2) it openly 
discusses the important and challenging aspects of clinical translation and trial design, and 3) it 
finally seeks to harmonise the work being done, and design all the planned work and trials so that 
they can be compared to maximise what can be learnt from them. This year we concentrated on 4 
key issues:   
-Immunosuppressive regime The immunogenicity of dopaminergic neurons derived from hPSC 
sources is unknown, and it is thus unclear what the optimal immunosuppressive regime would look 
like in any clinical trial using these cells. The general consensus is that a period of 
immunosuppression is needed and will involve using a least one immunosuppressive agent, such as 
FK506, for 1-2 years post grafting as outlined in Table 1. This is based in part on the current regimes 
being used in patients in receipt of hfVM transplants, where long term graft survival has been seen 
in some PD patients without the need for lifetime immunosuppression. In addition, it has been 
shown that triple immunotherapy for a year post grafting results in better graft dopaminergic cell 
survival compared with no immunosuppression or monotherapy with CyA for only 6 months post 
grafting. 
-Patient selection The choice of patients for any first in human study with hPSC derived dopamine 
cells is not straightforward. They need to demonstrate a clear response to oral dopamine 
medications, but when in the disease course should they be treated with this new experimental 
therapy?  Some argue that the ideal cohort should capture patients that are most likely to get 
maximal benefit from their transplant, similar to the ones enrolled for the TRANSEURO study, 
namely, younger patients with less advanced disease and no significant L-dopa induced dyskinesias 
(LIDs), as well as no cognitive deficits predictive of early dementia and a good response to 
dopaminergic medications (Barker et al., 2015). However, others will argue that subjecting patients 
to an unproven stem cell therapy at this stage of their illness is unethical and that instead the 
treatment should be trialled in those with more advanced disease and motor fluctuations, given that 
they are at a stage of their illness where a more invasive therapeutic approach is needed (e.g. DBS or 
apomorphine/DuoDopa®). In addition, it will be easier to monitor efficacy in this latter group of 
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patients compared to patients with milder disease where responses to drug therapies are often 
excellent and sustained, although this clearly creates a therapeutic conundrum as to whether 
clinicians/patients should opt for an established therapy such as DBS or more experimental, 
unproven cell based approaches. At the moment, most groups are erring on the side of choosing 
patients with slightly more advanced disease compared to TRANSEURO, but not so advanced that 
they have significant LIDs.     
- Patient assessment The protocol for assessing patients will include a comprehensive set of 
standard motor, cognitive, psychiatric, non-motor, and quality of life assessments as outlined in 
table 1, all of which exist for PD and are well validated (TRANSEURO: NCT01898390). Indeed, several 
groups have already started an observational study using these assessments in new cohorts of PD 
patients with the aim of randomly recruiting some of them into the planned trials. This not only 
facilitates the clinical trial once regulatory approval has been granted, but also generates a clinically 
matched comparator arm by which to analyse any early signs of clinical efficacy with the new 
therapy. 
In addition to these clinical tests, imaging will be required for two purposes: ensuring safety using 
MRI and monitoring the dopamine content of the transplant using  PET or an equivalent.  MRI safety 
monitoring is likely to occur at least 3 monthly for the first year after grafting, then 6 monthly for 3 
years, and annually thereafter. PET imaging is likely to employ 18F-dopa and/or 11CPE2i, although 
some groups may pursue additional measures to look not only at the dopaminergic cells in the graft 
but also at cell proliferation and microglial activation as outlined in Table 1. 
-Trial design The first in human studies will be open label and also involve a dose finding element 
with small numbers of patients. Most groups are thinking of recruiting no more than 12 patients for 
these phase1/2a studies, with 2 different doses of cells being given across this group (see Table 1). 
None of the groups plan for sham surgery in these initial dose-finding trials, and the use of 
sham/imitation surgery at later stages is an active area of discussion as is the need to show that this 
therapy has therapeutic equivalence or superiority to that which already exists for PD, including DBS 
and advanced forms of DA delivery. This can be studied in part by using a nested trial design with 
patients recruited for the new intervention coming from a well matched larger cohort of patients, all 
of whom are assessed in identical ways. 
The primary end point for all these trials will be tolerability and feasibility, as they will not be 
sufficiently powered to show safety and/or efficacy. In addition, as with any such cell therapy, any 
signs of clinical efficacy may take up to 3-5 years to be maximally evident based on what is observed 
with hfVM transplants, and thus cannot be a primary end point in these early trials, especially given 
the absence of any sham surgery control arm. Thus, most groups will wait at least 2 years post 
grafting before publishing their results so that better measures of tolerability can be reported as well 
as any signs of clinical potency, although it should be stated that patients should ideally be followed 
up indefinitely until death given the irreversible nature of intracerebral neural grafting.  
The dawn of a new era? 
Treating Parkinson’s disease using new, manufactured dopamine cells has been a goal since the first 
pioneering clinical transplantation studies using fetal cells more than 25 years ago. The limitation of 
using fetal tissue was already recognized at this time, and so began the long journey to find a 
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scalable, ethically acceptable, safe cell source. En route, other neuronal alternatives have been 
considered including ex vivo expanded fetal human VM DA neuroblasts and xenotransplants of pig 
VM tissue, but these sources have met with only limited success.  
The derivation of the first hESCs in 1998 brought with it a new hope that this could be the source 
from which authentic human midbrain DA neurons could be derived. However, this achievement 
took longer than expected, with two groups reporting protocols in 2011-2012 with long term 
survival and functional efficacy in animal models of PD (Kirkeby et al., 2012; Kriks et al., 2011). These 
studies were a turning point in the field and catalyzed the development of new protocols with a 
realistic expectation that this approach can now be considered for clinical trials. However, only in 
the last year has this goal become a reality, with the GMP cell manufacturing either already 
completed or in progress. Thus, we are entering the last phase of pre-clinical work with clinical trials 
planned in 2018 and in the years thereafter, and as such the use of stem cells for PD has entered a 
new era. 
 
TABLE 1- Main feature summary of GFORCE PD partners’ clinical trials 
 
 
 EUROPEAN STEM-
PD* 
NYSTEM-PD CiRA TRIAL SUMMIT FOR 
PD TRIAL 
CELL SOURCE ES ES Allogeneic iPS Autologous iPS 
CRYOPRESERVED 
CELL PRODUCT? 
YES YES NO YES 
GENETIC TESTING 
OF CELL PRODUCT 
TBD Karyotype / + 
TBD 
Sequencing for 
certain genes 
Full genome seq 
CELL DELIVERY 
METHOD 
“Rehncrona” 
instrument 
previously used in 
fetal VM trials 
MRI/Clearpoint 
system 
Purpose made 
needle 
MRI/Clearpoint 
system 
DOSING? Low dose 
High dose 
Low dose 
High dose 
One dose Low dose 
High dose 
IMMUNO-
SUPPRESSIVE 
REGIME 
Yes, at least 12 
months 
Probably 
CiclosporinA; 
Azathioprine; 
Steroids 
Yes, 12 months 
FK506; 
Basiliximab;  
TBD +/- 
mycophenolate  
Yes, 1-2 years 
FK506 
None 
PATIENT 
CHARACTERISTICS 
Age 
Disease Duration 
Significant LIDs? 
L-dopa response? 
 
 
 
<70 years old 
<12 years 
No 
>30% 
 
 
40-70 years old 
5-12 years 
No 
>50% 
 
 
50-70 years old 
>5 years 
No 
>30% 
 
 
45-70 years 
>5 years 
No 
>20% 
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PRE TRANSPLANT 
RUN IN PERIOD 
>1 year >1 year TBD >1 year 
FOLLOW UP PERIOD Indefinitely At least 2 years At least 2 years At least 1 year 
PET IMAGING F-dopa;  
PE2i 
F-dopa;  
PE2i;  
DPA 713 
F-dopa;  
DAT-SPECT;  
FLT 
GE180 
F-dopa; 
DAT-SPECT 
FLT 
GE180 
PRIMARY END 
POINT 
Adverse events Adverse events Adverse events Adverse events 
SECONDARY 
CLINICAL END 
POINTS (changes in) 
UPDRS motor 3 in 
defined “off”; 
PDQ39; 
Addenbrooke’s 
Cognitive 
Examination 
(Revised) 
 
UPDRS motor 3 
in defined “off”; 
PDQ39; 
Montreal 
Cognitive 
Assessment 
 
UPDRS motor 3 
in defined “off”; 
“off” time 
period 
PDQ39; 
Mini Mental 
State 
Examination 
score 
 
UPDRS motor 3 
in defined “off”; 
PDQ39; 
Mini Mental 
State 
Examination 
Score  
DATE FOR PLANNED 
FIRST IN HUMAN 
STUDY 
2019-2020 2018 2018 2020 
* the outcome of NeuroStemCellRepair and TRANSEURO
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Figure Legend: 
Figure 1: Overview of cells for clinical trials                                                                                     
Possible donor cells explored within GForce PD include human embryonic stem cells (ES cells) and 
induced pluripotent stem cells (iPS cells) from non-matched or HLA-matched donors (left side) as 
well as patient specific iPS cells (right side). 
